long term effects of glp 1 agonists Mapping the effectiveness and risks GLP-1 receptor Impact of GLP- 1 Receptor

Osmotic laxatives

Available options include GLP-1 receptor agonists such as semaglutide (2.4 mg weekly dose) and the dual GLP-1/GIP receptor agonist tirzepatide

The United States is anticipated to grow at a CAGR of 5.2% from 2026 to 2036, supported by increasing diabetic prevalence, ongoing research in diabetes treatment, and widespread adoption of GLP-1 receptor agonists in managing type 2 diabetes

GLP-1 medication does not directly cause hair loss

Back Deacon, DF, Johnsen, AH, Holst, JJ (March 1995) 'Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo', Journal Clinical Endocrinology Metabolism , 80/3, 952-7